Avenue Therapeutics share price today

(ATXI)

Avenue Therapeutics share price is $1.72 & ₹146.54 as on 25 Dec 2024, 2.30 'hrs' IST

$1.72

▲

-0.08

(-4.44%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Avenue Therapeutics share price in Dollar and Rupees. Guide to invest in Avenue Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Avenue Therapeutics. Get details on the Indian mutual funds that are investing in Avenue Therapeutics. Get Analyst recommendations and forecasts along with all the Avenue Therapeutics's financials.

Avenue Therapeutics share price movements

Today's Low: $1.71
Today's High: $1.80
$1.72
0.58%
Downside
Day's Volatility :4.74%
Upside
4.18%
52 Weeks Low: $1.60
52 Weeks High: $26.47
$1.72
6.98%
Downside
52 Weeks Volatility :93.95%
Upside
93.5%

Avenue Therapeutics Returns

Period	Avenue Therapeutics Inc	Index (Russel 2000)
3 Months	-26.65%	0.0%
6 Months	-51.96%	0.0%
1 Year	-85.92%	0.0%
3 Years	-99.84%	-21.1%

Avenue Therapeutics Key Statistics

in dollars & INR

Previous Close	$1.8
Open	$1.74
Today's High	$1.795
Today's Low	$1.71
Market Capitalization	$3.5M
Today's Volume	$19.6K
52 Week High	$26.4675
52 Week Low	$1.6
Revenue TTM	$0.0
Earnings Per Share (EPS)	$24.78
PE Ratio	0.07
Profit Margin	0.0%
Quarterly Earnings Growth YOY	-0.76%
Return On Equity TTM	-535.1%

How to invest in Avenue Therapeutics from India?

It is very easy for Indian residents to invest directly in Avenue Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Avenue Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Avenue Therapeutics or ATXI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Avenue Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Avenue Therapeutics shares which would translate to 0.495 fractional shares of Avenue Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Avenue Therapeutics, in just a few clicks!

Returns in Avenue Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Avenue Therapeutics investment value today

Current value as on today

₹16,314

Returns

₹83,686

(-83.69%)

Returns from Avenue Therapeutics Stock

₹85,925 (-85.92%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Avenue Therapeutics

52%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Avenue Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 52% more investors are searching Avenue Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Avenue Therapeutics

Armistice Capital, LLC
6.02%
Sabby Management LLC
1.96%
Moss Adams Wealth Advisors LLC
0.58%
UBS Group AG
0.32%
Tower Research Capital LLC
0.09%
Wells Fargo & Co
0.03%

Analyst Recommendation on Avenue Therapeutics

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Avenue Therapeutics(by analysts ranked 0 to 5 stars)

Based on 8 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Avenue Therapeutics

What analysts predicted

Upside of 365.12%

Current:

$1.72

Target:

$8.00

Insights on Avenue Therapeutics

Price Movement
In the last 7 days, ATXI stock has moved down by -4.4%
ATXI vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 113.0%
ATXI vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 125.1%

Avenue Therapeutics Technicals Summary

Sell

Neutral

Buy

Avenue Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Avenue Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Avenue Therapeutics Inc	-15.69%	-51.96%	-85.92%	-99.84%	-99.98%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Avenue Therapeutics Inc	0.07	0.07	0.0	0.0	-5.35	-2.01	NA	4.64
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Avenue Therapeutics Inc	Buy	$3.5M	-99.98%	0.07	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Avenue Therapeutics

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

Organization	Avenue Therapeutics
Employees	3
CEO	Dr. Alexandra MacLean M.D.
Industry	Health Technology

Management People of Avenue Therapeutics

Name	Title
Dr. Alexandra MacLean M.D.	CEO & Director
Mr. David Jin	Interim CFO, COO & Corporate Secretary
Dr. Lindsay Allan Rosenwald	Executive Director
Dr. Scott A. Reines M.D., Ph.D.	Interim Chief Medical Officer

Important FAQs about investing in Avenue Therapeutics from India :

What is Avenue Therapeutics share price today?

Avenue Therapeutics share price today stands at $1.72, Open: $1.74 ; Previous Close: $1.80 ; High: $1.80 ; Low: $1.71 ; 52 Week High: $26.47 ; 52 Week Low: $1.60. The stock opens at $1.74, after a previous close of $1.80. The stock reached a daily high of $1.80 and a low of $1.71, with a 52-week high of $26.47 and a 52-week low of $1.60.

Can Indians buy Avenue Therapeutics shares?

Yes, Indians can invest in the Avenue Therapeutics (ATXI) from India.

With INDmoney, you can buy Avenue Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Avenue Therapeutics at zero transaction cost.

How can I buy Avenue Therapeutics shares from India?

It is very easy to buy Avenue Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Avenue Therapeutics be purchased?

Yes, you can buy fractional shares of Avenue Therapeutics with INDmoney app.

What are the documents required to start investing in Avenue Therapeutics stocks?

To start investing in Avenue Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.